Morning Lantus [insulin glargine] v. intermediate-acting insulin 2x/day as basal insulin in a muliple daily inj. w/ Humalog [insulin lispro] in adolescents w/ type 1 diabetes mellitus: an active-controlled, open, randomized, gender-stratified, two-arm, parallel-group study
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Insulin glargine (Primary) ; Insulin suspension isophane; Insulin zinc suspension
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Aventis Pharmaceuticals; Sanofi
- 01 Mar 2009 Pharmacodynamic substudy published in Diabetes Care.
- 05 Aug 2008 The expected completion date for this trial is now 1 Feb 2005.
- 15 Sep 2006 New trial record.